Centrum Badan Klinicznych Pi-House Sp. z o.o.
- Address
- Ul. Na Zaspe 3, 80-546 Gdansk, Poland
Cardiovascular Diseases
The site is conducting studies that target heart‑related health, especially conditions linked to weight and blood‑sugar control.
- Obesity management with novel weight‑loss agents
- Type 2 diabetes combination therapies to improve glycemic control
- Metabolic dysfunction‑associated steatotic liver disease interventions
With 98 trials and 32 investigators, Centrum Badan Klinicznych Pi‑House in Gdansk is a key hub for cardiovascular research in Europe.
Hormonal Diseases
Research focuses on endocrine disorders that affect metabolism and quality of life.
- Type 2 diabetes mellitus adjunctive treatments
- Obesity and overweight interventions
- Hormonal regulation in menstrual migraine
The trials aim to improve hormone‑based therapies and are run by a multidisciplinary team at the Gdansk facility.
Immune System Diseases
Studies evaluate new ways to modulate immune responses in skin and allergic conditions.
- Atopic dermatitis biologic and JAK‑inhibitor trials
- Psoriasis and chronic hand eczema therapies
- Chronic spontaneous urticaria novel antihistamine strategies
- Hidradenitis suppurativa targeted treatments
- Vitiligo regenerative approaches
These immune‑focused trials seek to reduce inflammation and improve skin health for patients across Poland.
Musculoskeletal Diseases
The program addresses joint and spine disorders that limit daily activity.
- Rheumatoid arthritis disease‑modifying studies
- Psoriatic arthritis biologic comparisons
- Chronic low back pain non‑opioid analgesic evaluation
- Active psoriatic arthritis outcome measures
By exploring both inflammatory and mechanical causes, the trials aim to restore mobility and reduce pain.
Nervous System Diseases
Investigations target neurodegenerative and seizure disorders, seeking disease‑modifying options.
- Alzheimer disease early‑stage therapeutic trials
- Epilepsy refractory focal onset and generalized tonic‑clonic seizures
- Tourette syndrome symptom‑reduction studies
- Mild cognitive impairment progression prevention
The goal is to slow cognitive decline and improve seizure control for affected individuals.
Nutritional and Metabolic Diseases
Clinical work explores how diet‑related conditions intersect with metabolic health.
- Obesity pharmacologic and lifestyle combos
- Type 2 diabetes multi‑drug regimens
- Metabolic dysfunction‑associated steatotic liver disease novel agents
These studies aim to reduce disease burden through improved metabolic regulation.
Otorhinolaryngologic Diseases
Research includes conditions affecting the upper airway and related immune responses.
- Chronic spontaneous urticaria with ENT manifestations
- Allergic rhinitis adjunct therapies
- Nasal inflammation in obstructive sleep apnoea
The trials aim to improve breathing comfort and reduce inflammation in the head‑neck region.
Skin and Connective Tissue Diseases
A broad portfolio targets inflammatory skin disorders and connective‑tissue conditions.
- Atopic dermatitis long‑term safety of emerging biologics
- Psoriasis cream and systemic options
- Hidradenitis suppurativa phase studies
- Alopecia areata hair‑regrowth interventions
By addressing skin barrier function and immune pathways, the research seeks durable remission for patients.
Metabolism (Phenomena and Processes)
Investigations focus on the biochemical pathways that underlie weight and glucose regulation.
- Energy balance in obesity treatment
- Insulin sensitivity enhancement in type 2 diabetes
- Lipid metabolism modulation in steatotic liver disease
The aim is to translate metabolic insights into effective therapeutic options.
Behavior and Behavior Mechanisms
Studies examine how brain circuits influence mood and motivation, testing new psychiatric agents.
- Adjunctive aticaprant for anhedonia in major depressive disorder
- Pimavanserin safety in children with autism spectrum disorder
- Atogepant preventive treatment for menstrual migraine
These trials aim to restore normal behavior patterns and alleviate depressive or anxiety symptoms.
Mental Disorders
Clinical programs target severe psychiatric conditions with innovative pharmacologic approaches.
- Schizophrenia negative‑symptom modulation
- Treatment‑resistant depression combined with psychological support
- Generalized anxiety disorder acute symptom relief
- Obsessive‑compulsive disorder novel agent evaluation
The goal is to provide effective relief for patients whose symptoms persist despite standard care.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 5 of 13 therapeutic areas and 15 of 106 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 101 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 31 by active trials.
- 1Eli Lilly & Co.6active
lock +30 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Eli Lilly & Co.18trials
lock +25 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 1 624 other sites in Poland
Therapeutic Area Benchmark — Poland
Select a therapeutic area to compare against other sites in Poland.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Poland
Market Share
Country: Poland
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Centrum Badan Klinicznych Pi-House Sp. z o.o.
lock Showing 1 of 126 trials — the rest is available on a paid plan.
IMP list
lock Showing 1 of 106 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Amlitelimab | 4 | Unknown | 2022-11-10 | 2024-10-30 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.